{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:28:53Z","timestamp":1659086933718},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.eimc.2014.05.012","type":"journal-article","created":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T06:19:13Z","timestamp":1407910753000},"page":"331-336","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incidencia, manejo y coste de los efectos adversos hematol\u00f3gicos y dermatol\u00f3gicos durante las 12primeras semanas de tratamiento con triple terapia para hepatitisC"],"prefix":"10.1016","volume":"33","author":[{"given":"Beatriz","family":"Guglieri-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Ventura-Cerd\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"G\u00f3mez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Climente-Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2014.05.012_bib0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the Study of Liver Diseases Diagnosis, Management, and Treatment of HepatitisC: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2014.05.012_bib0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitisC virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2014.05.012_bib0015","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eimc.2014.05.012_bib0020","unstructured":"Merck & Co. FDA Antiviral Drugs Advisory Committee Meeting. Boceprevir Capsules (NDA 202-258). Brie\ufb01ng Document. Silver Spring, MD: U.S. Food and Drug Administration; 29 March 2011 [consultado 3 Nov 2011]. Disponible en: www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM252343.pdf"},{"key":"10.1016\/j.eimc.2014.05.012_bib0025","unstructured":"Vertex Pharmaceuticals. Telaprevir 375-mg Film-Coated Tablet for the Treatment of Genotype 1 Chronic Hepatitis C. Antiviral Drugs Advisory Committee. Brie\ufb01ng Document (NDA 201-917). Silver Spring, MD: U.S. Food and Drug Administration; 28 April 2011 [consultado 3 Nov 2011]. Disponible en: www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM252562.pdf"},{"key":"10.1016\/j.eimc.2014.05.012_bib0090","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitisC virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.eimc.2014.05.012_bib0095","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitisC virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.05.012_bib0100","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.05.012_bib0105","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.05.012_bib0110","unstructured":"Real Decreto-ley 8\/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducci\u00f3n del d\u00e9ficit p\u00fablico. Fecha de publicaci\u00f3n: Lunes 24 de mayo de 2010. Cap\u00edtulo V: P\u00e1g. 45118-45120."},{"key":"10.1016\/j.eimc.2014.05.012_bib0115","unstructured":"DECRETO LEGISLATIVO 1\/2005, de 25 de febrero, del Consell de la Generalitat, por el que se aprueba el Texto Refundido de la Ley de Tasas de la Generalitat. [2005\/3015] (DOCV n\u00fam. 4971 de 22.03.2005). P\u00e1gs. 9589-9615."},{"key":"10.1016\/j.eimc.2014.05.012_bib0120","unstructured":"LEY 9\/2011, de 26 de diciembre, de Medidas Fiscales, de Gesti\u00f3n Administrativa y Financiera, y de Organizaci\u00f3n de la Generalitat [2011\/13102] (DOCV n\u00fam. 6680 de 28.12.2011). P\u00e1gs. 41968-41984."},{"key":"10.1016\/j.eimc.2014.05.012_bib0065","first-page":"125","article-title":"Managing adverse effects and complications in completing treatment for hepatitisC virus infection","volume":"20","author":"Sherman","year":"2012","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.eimc.2014.05.012_bib0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1155\/2006\/497059","article-title":"Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitisC virus being treated with ribavirin","volume":"20","author":"Sherman","year":"2006","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.eimc.2014.05.012_bib0075","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2011.08.006","article-title":"Dermatological side effects of hepatitisC and its treatment: Patient management in the era of direct-acting antivirals","volume":"56","author":"Cacoub","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.eimc.2014.05.012_bib0080","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitisC virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2014.05.012_bib0085","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X14002146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X14002146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:51:17Z","timestamp":1538355077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X14002146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0213005X14002146"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2014.05.012","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidencia, manejo y coste de los efectos adversos hematol\u00f3gicos y dermatol\u00f3gicos durante las 12primeras semanas de tratamiento con triple terapia para hepatitisC","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2014.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Espa\u00f1a, S.L.U. y Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}